{
  "ticker": "ENTA",
  "company_name": "Enanta Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT00990145",
      "title": "Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "MRSA, SSTI",
      "start_date": "2008-11",
      "completion_date": "2009-09",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT03187496",
      "title": "Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "NASH",
      "start_date": "2017-05-11",
      "completion_date": "2017-06-14",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT03783897",
      "title": "A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "NASH - Nonalcoholic Steatohepatitis",
      "start_date": "2018-11-27",
      "completion_date": "2019-06-18",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT00270517",
      "title": "Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia",
      "status": "UNKNOWN",
      "phase": "PHASE2",
      "condition": "Community Acquired Pneumonia",
      "start_date": "2005-12",
      "completion_date": "2007-07",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT06917508",
      "title": "A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "RSV Infection, Drug Drug Interaction",
      "start_date": "2025-03-13",
      "completion_date": "2025-06-13",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT03748628",
      "title": "Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "NASH - Nonalcoholic Steatohepatitis",
      "start_date": "2018-10-05",
      "completion_date": "2018-10-13",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT03384823",
      "title": "A Study of EDP-938 in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "RSV Infection",
      "start_date": "2017-12-07",
      "completion_date": "2018-07-03",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT04633187",
      "title": "Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Respiratory Syncytial Virus Infections",
      "start_date": "2021-07-07",
      "completion_date": "2023-05-31",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT01856426",
      "title": "Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hepatitis C",
      "start_date": "2013-06",
      "completion_date": "2015-10",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT04971512",
      "title": "A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Chronic Hepatitis B Virus Infection",
      "start_date": "2021-08-02",
      "completion_date": "2021-12-20",
      "enrollment": 0,
      "sponsor": "Enanta Pharmaceuticals, Inc"
    }
  ],
  "summary": {
    "total_trials": 43,
    "by_phase": {
      "PHASE1": 32,
      "PHASE2": 11
    },
    "by_status": {
      "COMPLETED": 38,
      "UNKNOWN": 1,
      "TERMINATED": 4
    },
    "active_trials": 0,
    "completed_trials": 38,
    "conditions": [
      "COVID-19",
      "Chronic HBV Infection",
      "Chronic Hepatitis B Virus Infection",
      "Community Acquired Pneumonia",
      "Healthy",
      "Hepatitis B",
      "Hepatitis C",
      "Hepatitis C Virus",
      "MRSA, SSTI",
      "NASH",
      "NASH - Nonalcoholic Steatohepatitis",
      "NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis",
      "Non-Alcoholic Steatohepatitis",
      "Presumptive NAFLD",
      "Primary Biliary Cholangitis",
      "RSV Infection",
      "RSV Infection, Drug Drug Interaction",
      "RSV Infection, Drug Drug Interaction (DDI)",
      "RSV Infection, QTc Interval",
      "Respiratory Syncytial Virus",
      "Respiratory Syncytial Virus (RSV)",
      "Respiratory Syncytial Virus Infections",
      "SARS CoV 2 Infection",
      "Safety in Normal Volunteers",
      "Skin and Soft Tissue Infections, Methicillin-resistant Staphylococcus Aureus"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:09.440977",
    "search_query": "Enanta Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Enanta+Pharmaceuticals,+Inc."
  }
}